Valuation: Nektar Therapeutics

Market Cap 1.41B 1.26B 1.17B 1.06B 2.01B 136B 2.01B 14.06B 5.51B 69.36B 5.28B 5.16B 223B P/E 2026 *
-5.12x
P/E 2027 * -3.97x
Enterprise Value 1.32B 1.18B 1.09B 996M 1.88B 128B 1.89B 13.18B 5.16B 65.02B 4.95B 4.84B 209B EV / Sales 2026 *
31.4x
EV / Sales 2027 * 21.3x
Free-Float
99.62%
Yield 2026 *
-
Yield 2027 * -
1 day+0.91%
1 week-5.53%
Current month-32.00%
1 month-41.73%
3 months-41.49%
6 months-46.88%
Current year-2.63%
1 week 38.44
Extreme 38.445
43.5
1 month 38.44
Extreme 38.445
70
Current year 33.4
Extreme 33.4
109
1 year 33.4
Extreme 33.4
109
3 years 6.19
Extreme 6.188996
109
5 years 6.19
Extreme 6.188996
268.65
10 years 6.19
Extreme 6.188996
1,670.4
Manager TitleAgeSince
Chief Executive Officer 73 01/01/2007
Director of Finance/CFO 60 15/05/2026
Chief Tech/Sci/R&D Officer 52 01/07/2015
Director TitleAgeSince
Director/Board Member 72 01/08/2000
Chairman 69 01/05/1992
Director/Board Member 73 01/02/2007
Date Insider Type Main position Quantity % Market Cap. Importance
9/23/26 A Free

Director

6,000 0.0176%
9/23/26 A Free

Director

6,000 0.0176%
9/23/26 A Free

Director

6,000 0.0176%
Change 5-day change 1-year change 3-year change Capi.($)
+0.91%-5.53%-24.24%+408.27% 1.41B
-2.59%-5.70%+50.69%+86.86% 70.61B
+3.23%-10.67%+6.27%+53.70% 51.01B
+1.56%+1.17%+8.49%+31.81% 48.1B
+0.39%+0.65%+31.14%+28.97% 42.78B
+0.87%-8.17%+293.37%+642.41% 40.67B
+1.24%-1.01%+10.74%+100.64% 40.3B
-2.13%-1.64%+8.63%+46.88% 30.59B
-0.46%-1.28%+42.23%+20.34% 28.16B
+5.32%+0.06%-5.00%-12.78% 24.36B
Average +0.83%-2.94%+42.23%+140.71% 37.8B
Weighted average by Cap. +0.56%-2.95%+51.07%+116.66%

Financials

2026 *2027 *
Net sales 42M 37.51M 34.9M 31.74M 59.93M 4.07B 60.19M 420M 165M 2.07B 158M 154M 6.65B 55.99M 50M 46.52M 42.31M 79.89M 5.42B 80.23M 560M 219M 2.76B 210M 206M 8.87B
Net income -244M -218M -203M -184M -348M -23.6B -349M -2.44B -955M -12.03B -916M -896M -38.6B -359M -320M -298M -271M -512M -34.73B -514M -3.59B -1.41B -17.71B -1.35B -1.32B -56.82B
Net Debt -88.02M -78.61M -73.13M -66.51M -126M -8.52B -126M -880M -345M -4.34B -331M -323M -13.94B -210M -188M -175M -159M -300M -20.36B -301M -2.1B -824M -10.38B -790M -773M -33.31B
Projected Income Statement - Annual - Nektar Therapeutics
Logo Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Employees
63
Date Price Change Volume
09/10/26 $41.17 +0.91% 1,174,741
08/10/26 $40.80 +1.34% 1,749,656
07/10/26 $40.26 +0.88% 1,510,549
06/10/26 $39.91 -5.47% 1,957,185
05/10/26 $42.22 -3.12% 2,029,306
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Ratings Surperformance© - Nektar Therapeutics
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
41.17USD
Average target price
141.40USD
Spread / Average Target
+243.45%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Nektar Therapeutics
  1. Stock Market
  2. Stocks
  3. NKTR Stock